Marie‐Christine Kaminsky

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

Jean‐Pascal Machiels, Stéphanie Henry, Sylvie Zanetta et al. · Journal of Clinical Oncology · 2009 · 169 citations · Full text

Oncologic Imaging, Sunitinib Monotherapy, Dce-mri Monitoring +14

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun et al. · Annals of Oncology · 2022 · 166 citations · Full text

Ii Trial, Radiation Medicine, Radiation Therapy +10

Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)

Stéphane Culine, Alain Lortholary, Jean‐Jacques Voigt et al. · Journal of Clinical Oncology · 2003 · 151 citations